BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 24756794)

  • 1. Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor.
    Grüllich C
    Recent Results Cancer Res; 2014; 201():207-14. PubMed ID: 24756794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cabozantinib: Multi-kinase Inhibitor of MET, AXL, RET, and VEGFR2.
    Grüllich C
    Recent Results Cancer Res; 2018; 211():67-75. PubMed ID: 30069760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.
    Bentzien F; Zuzow M; Heald N; Gibson A; Shi Y; Goon L; Yu P; Engst S; Zhang W; Huang D; Zhao L; Vysotskaia V; Chu F; Bautista R; Cancilla B; Lamb P; Joly AH; Yakes FM
    Thyroid; 2013 Dec; 23(12):1569-77. PubMed ID: 23705946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer.
    Krajewska J; Olczyk T; Jarzab B
    Expert Rev Clin Pharmacol; 2016; 9(1):69-79. PubMed ID: 26536165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cabozantinib in Thyroid Cancer.
    Fallahi P; Ferrari SM; Di Bari F; Materazzi G; Benvenga S; Miccoli P; Antonelli A
    Recent Pat Anticancer Drug Discov; 2015; 10(3):259-69. PubMed ID: 26152149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.
    Yakes FM; Chen J; Tan J; Yamaguchi K; Shi Y; Yu P; Qian F; Chu F; Bentzien F; Cancilla B; Orf J; You A; Laird AD; Engst S; Lee L; Lesch J; Chou YC; Joly AH
    Mol Cancer Ther; 2011 Dec; 10(12):2298-308. PubMed ID: 21926191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.
    Varkaris A; Corn PG; Parikh NU; Efstathiou E; Song JH; Lee YC; Aparicio A; Hoang AG; Gaur S; Thorpe L; Maity SN; Bar Eli M; Czerniak BA; Shao Y; Alauddin M; Lin SH; Logothetis CJ; Gallick GE
    Clin Cancer Res; 2016 Jan; 22(1):107-21. PubMed ID: 26272062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cabozantinib: Mechanism of action, efficacy and indications].
    Cochin V; Gross-Goupil M; Ravaud A; Godbert Y; Le Moulec S
    Bull Cancer; 2017 May; 104(5):393-401. PubMed ID: 28477875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.
    Kurzrock R; Sherman SI; Ball DW; Forastiere AA; Cohen RB; Mehra R; Pfister DG; Cohen EE; Janisch L; Nauling F; Hong DS; Ng CS; Ye L; Gagel RF; Frye J; Müller T; Ratain MJ; Salgia R
    J Clin Oncol; 2011 Jul; 29(19):2660-6. PubMed ID: 21606412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.
    Sherman SI; Clary DO; Elisei R; Schlumberger MJ; Cohen EE; Schöffski P; Wirth LJ; Mangeshkar M; Aftab DT; Brose MS
    Cancer; 2016 Dec; 122(24):3856-3864. PubMed ID: 27525386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ONC201 Shows Potent Anticancer Activity Against Medullary Thyroid Cancer via Transcriptional Inhibition of
    Bagheri-Yarmand R; Dadu R; Ye L; Shiny Jebaraj Y; Martinez JA; Ma J; Tarapore RS; Allen JE; Sherman SI; Williams MD; Gagel RF
    Mol Cancer Ther; 2021 Apr; 20(4):665-675. PubMed ID: 33536187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.
    Goyal L; Zheng H; Yurgelun MB; Abrams TA; Allen JN; Cleary JM; Knowles M; Regan E; Reardon A; Khachatryan A; Jain RK; Nardi V; Borger DR; Duda DG; Zhu AX
    Cancer; 2017 Jun; 123(11):1979-1988. PubMed ID: 28192597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).
    Bowles DW; Kessler ER; Jimeno A
    Drugs Today (Barc); 2011 Nov; 47(11):857-68. PubMed ID: 22146228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CABOCOL-01 trial: a single-arm phase II study assessing safety and efficacy of Cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure.
    Coquan E; Brachet PE; Licaj I; Leconte A; Castera M; Lequesne J; Meriaux E; Bonnet I; Lelaidier A; Clarisse B; Joly F
    BMC Cancer; 2021 Sep; 21(1):1054. PubMed ID: 34563169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cabozantinib in progressive medullary thyroid cancer.
    Elisei R; Schlumberger MJ; Müller SP; Schöffski P; Brose MS; Shah MH; Licitra L; Jarzab B; Medvedev V; Kreissl MC; Niederle B; Cohen EE; Wirth LJ; Ali H; Hessel C; Yaron Y; Ball D; Nelkin B; Sherman SI
    J Clin Oncol; 2013 Oct; 31(29):3639-46. PubMed ID: 24002501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cabozantinib: a review of its use in patients with medullary thyroid cancer.
    Hoy SM
    Drugs; 2014 Aug; 74(12):1435-44. PubMed ID: 25056653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve
    Wirth LJ; Brose MS; Elisei R; Capdevila J; Hoff AO; Hu MI; Tahara M; Robinson B; Gao M; Xia M; Maeda P; Sherman E
    Future Oncol; 2022 Sep; 18(28):3143-3150. PubMed ID: 35969032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cabozantinib in genitourinary malignancies.
    Zhang T; Park SE; Hong C; George DJ
    Future Oncol; 2017 Apr; 13(8):755-765. PubMed ID: 27842445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study.
    Tolaney SM; Nechushtan H; Ron IG; Schöffski P; Awada A; Yasenchak CA; Laird AD; O'Keeffe B; Shapiro GI; Winer EP
    Breast Cancer Res Treat; 2016 Nov; 160(2):305-312. PubMed ID: 27714541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cabozantinib for the treatment of advanced medullary thyroid cancer.
    Nagilla M; Brown RL; Cohen EE
    Adv Ther; 2012 Nov; 29(11):925-34. PubMed ID: 23104465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.